PURPOSE OF REVIEW: Chimeric antigen receptor (CAR) T cell therapy has been successful in some haematologic malignancies, but the central nervous system (CNS) presents unique obstacles to its use against tumours arising therein. This review discusses recent improvements in the delivery and design of these cells to improve the efficacy and safety of this treatment against malignant gliomas. RECENT FINDINGS: The immunosuppressive environment of the CNS affects the functionality of CAR T cells, but recent developments using metabolic manipulation and cytokine delivery have shown that the performance of CAR T cells can be improved in this environment. Emerging techniques can improve the delivery of CAR T cells to the CNS parenchyma, which is normally well protected from peripheral immune cells. The implementation of novel antigens and CAR-expression regulation strategies will improve the specificity and efficacy of these cells. Finally, although autologous T cells have historically been the standard, recent developments have made the use of allogeneic T cells or natural killer (NK) cells more clinically feasible. SUMMARY: The discoveries highlighted in this review will aid the development of CAR cells that are safer, more resilient against immunosuppressive signals in the CNS, and able to specifically target intracranial tumour cells.
PURPOSE OF REVIEW: Chimeric antigen receptor (CAR) T cell therapy has been successful in some haematologic malignancies, but the central nervous system (CNS) presents unique obstacles to its use against tumours arising therein. This review discusses recent improvements in the delivery and design of these cells to improve the efficacy and safety of this treatment against malignant gliomas. RECENT FINDINGS: The immunosuppressive environment of the CNS affects the functionality of CAR T cells, but recent developments using metabolic manipulation and cytokine delivery have shown that the performance of CAR T cells can be improved in this environment. Emerging techniques can improve the delivery of CAR T cells to the CNS parenchyma, which is normally well protected from peripheral immune cells. The implementation of novel antigens and CAR-expression regulation strategies will improve the specificity and efficacy of these cells. Finally, although autologous T cells have historically been the standard, recent developments have made the use of allogeneic T cells or natural killer (NK) cells more clinically feasible. SUMMARY: The discoveries highlighted in this review will aid the development of CAR cells that are safer, more resilient against immunosuppressive signals in the CNS, and able to specifically target intracranial tumour cells.
Authors: Charly R Good; M Angela Aznar; Shunichiro Kuramitsu; Parisa Samareh; Sangya Agarwal; Greg Donahue; Kenichi Ishiyama; Nils Wellhausen; Austin K Rennels; Yujie Ma; Lifeng Tian; Sonia Guedan; Katherine A Alexander; Zhen Zhang; Philipp C Rommel; Nathan Singh; Karl M Glastad; Max W Richardson; Keisuke Watanabe; Janos L Tanyi; Mark H O'Hara; Marco Ruella; Simon F Lacey; Edmund K Moon; Stephen J Schuster; Steven M Albelda; Lewis L Lanier; Regina M Young; Shelley L Berger; Carl H June Journal: Cell Date: 2021-12-02 Impact factor: 66.850
Authors: Axel Hyrenius-Wittsten; Yang Su; Minhee Park; Julie M Garcia; Josef Alavi; Nathaniel Perry; Garrett Montgomery; Bin Liu; Kole T Roybal Journal: Sci Transl Med Date: 2021-04-28 Impact factor: 17.956
Authors: Fausta Ciccocioppo; Paola Lanuti; Laura Pierdomenico; Pasquale Simeone; Giuseppina Bologna; Eva Ercolino; Fabio Buttari; Roberta Fantozzi; Astrid Thomas; Marco Onofrj; Diego Centonze; Sebastiano Miscia; Marco Marchisio Journal: Sci Rep Date: 2019-06-19 Impact factor: 4.379
Authors: Robbie G Majzner; Sneha Ramakrishna; Kristen W Yeom; Shabnum Patel; Harshini Chinnasamy; Liora M Schultz; Rebecca M Richards; Li Jiang; Valentin Barsan; Rebecca Mancusi; Anna C Geraghty; Zinaida Good; Aaron Y Mochizuki; Shawn M Gillespie; Angus Martin Shaw Toland; Jasia Mahdi; Agnes Reschke; Esther H Nie; Isabelle J Chau; Maria Caterina Rotiroti; Christopher W Mount; Christina Baggott; Sharon Mavroukakis; Emily Egeler; Jennifer Moon; Courtney Erickson; Sean Green; Michael Kunicki; Michelle Fujimoto; Zach Ehlinger; Warren Reynolds; Sreevidya Kurra; Katherine E Warren; Snehit Prabhu; Hannes Vogel; Lindsey Rasmussen; Timothy T Cornell; Sonia Partap; Paul G Fisher; Cynthia J Campen; Mariella G Filbin; Gerald Grant; Bita Sahaf; Kara L Davis; Steven A Feldman; Crystal L Mackall; Michelle Monje Journal: Nature Date: 2022-02-07 Impact factor: 49.962
Authors: Pakawat Chongsathidkiet; Christina Jackson; Shohei Koyama; Franziska Loebel; Xiuyu Cui; S Harrison Farber; Karolina Woroniecka; Aladine A Elsamadicy; Cosette A Dechant; Hanna R Kemeny; Luis Sanchez-Perez; Tooba A Cheema; Nicholas C Souders; James E Herndon; Jean-Valery Coumans; Jeffrey I Everitt; Brian V Nahed; John H Sampson; Michael D Gunn; Robert L Martuza; Glenn Dranoff; William T Curry; Peter E Fecci Journal: Nat Med Date: 2018-08-13 Impact factor: 53.440